Abstract
BACKGROUND Vitamin D attenuates uremic cardiac hypertrophy, possibly by suppressing the myocardial renin-angiotensin system (RAS) and fibroblast growth factors (FGFs). We compared the suppression of cardiac hypertrophy and myocardial expression of RAS and FGF receptor genes offered by the vitamin D analog paricalcitol (Pc) or the angiotensin-converting enzyme inhibitor enalapril (E) in experimental uremia. METHODS Rats with 5/6 nephrectomy received Pc or E for 8 weeks. Renal function, systolic blood pressure, and cardiac hypertrophy were evaluated. Myocardial expression of RAS genes, brain natriuretic peptide (BNP), and FGF receptor-1 (FGFR-1) were determined using quantitative reverse-transcription (pRT)-PCR. RESULTS Blood pressure, proteinuria, and serum creatinine were significantly higher in untreated uremic animals. Hypertension was significantly reduced by E but only modestly by Pc; however, cardiac hypertrophy in the untreated group was similarly attenuated by Pc or E. Upregulation of myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in untreated uremic animals was reduced similarly by Pc and E, while the angiotensin II type 1 receptor was downregulated only by E. CONCLUSIONS Uremic cardiac hypertrophy is associated with activation of the myocardial RAS and the FGFR-1. Downregulation of these genes induced by Pc and E RESULTS in similar amelioration of left ventricular hypertrophy despite the different antihypertensive effects of these drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 720-726 |
| Number of pages | 7 |
| Journal | American Journal of Hypertension |
| Volume | 27 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- cardiac hypertrophy
- fibroblast growth factor
- paricalcitol.
- renin-angiotensin system
- uremia
- Vitamin D
ASJC Scopus subject areas
- Internal Medicine
Cite this
Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. / Freundlich, Michael; Li, Yan C.; Quiroz, Yasmir; Bravo, Yanauri; Seeherunvong, Wacharee; Faul, Christian H; Weisinger, Jose R.; Rodriguez-Iturbe, Bernardo.
In: American Journal of Hypertension, Vol. 27, No. 5, 01.01.2014, p. 720-726.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats
AU - Freundlich, Michael
AU - Li, Yan C.
AU - Quiroz, Yasmir
AU - Bravo, Yanauri
AU - Seeherunvong, Wacharee
AU - Faul, Christian H
AU - Weisinger, Jose R.
AU - Rodriguez-Iturbe, Bernardo
PY - 2014/1/1
Y1 - 2014/1/1
N2 - BACKGROUND Vitamin D attenuates uremic cardiac hypertrophy, possibly by suppressing the myocardial renin-angiotensin system (RAS) and fibroblast growth factors (FGFs). We compared the suppression of cardiac hypertrophy and myocardial expression of RAS and FGF receptor genes offered by the vitamin D analog paricalcitol (Pc) or the angiotensin-converting enzyme inhibitor enalapril (E) in experimental uremia. METHODS Rats with 5/6 nephrectomy received Pc or E for 8 weeks. Renal function, systolic blood pressure, and cardiac hypertrophy were evaluated. Myocardial expression of RAS genes, brain natriuretic peptide (BNP), and FGF receptor-1 (FGFR-1) were determined using quantitative reverse-transcription (pRT)-PCR. RESULTS Blood pressure, proteinuria, and serum creatinine were significantly higher in untreated uremic animals. Hypertension was significantly reduced by E but only modestly by Pc; however, cardiac hypertrophy in the untreated group was similarly attenuated by Pc or E. Upregulation of myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in untreated uremic animals was reduced similarly by Pc and E, while the angiotensin II type 1 receptor was downregulated only by E. CONCLUSIONS Uremic cardiac hypertrophy is associated with activation of the myocardial RAS and the FGFR-1. Downregulation of these genes induced by Pc and E RESULTS in similar amelioration of left ventricular hypertrophy despite the different antihypertensive effects of these drugs.
AB - BACKGROUND Vitamin D attenuates uremic cardiac hypertrophy, possibly by suppressing the myocardial renin-angiotensin system (RAS) and fibroblast growth factors (FGFs). We compared the suppression of cardiac hypertrophy and myocardial expression of RAS and FGF receptor genes offered by the vitamin D analog paricalcitol (Pc) or the angiotensin-converting enzyme inhibitor enalapril (E) in experimental uremia. METHODS Rats with 5/6 nephrectomy received Pc or E for 8 weeks. Renal function, systolic blood pressure, and cardiac hypertrophy were evaluated. Myocardial expression of RAS genes, brain natriuretic peptide (BNP), and FGF receptor-1 (FGFR-1) were determined using quantitative reverse-transcription (pRT)-PCR. RESULTS Blood pressure, proteinuria, and serum creatinine were significantly higher in untreated uremic animals. Hypertension was significantly reduced by E but only modestly by Pc; however, cardiac hypertrophy in the untreated group was similarly attenuated by Pc or E. Upregulation of myocardial expressions of renin, angiotensinogen, FGFR-1, and BNP in untreated uremic animals was reduced similarly by Pc and E, while the angiotensin II type 1 receptor was downregulated only by E. CONCLUSIONS Uremic cardiac hypertrophy is associated with activation of the myocardial RAS and the FGFR-1. Downregulation of these genes induced by Pc and E RESULTS in similar amelioration of left ventricular hypertrophy despite the different antihypertensive effects of these drugs.
KW - cardiac hypertrophy
KW - fibroblast growth factor
KW - paricalcitol.
KW - renin-angiotensin system
KW - uremia
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=84887224544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887224544&partnerID=8YFLogxK
U2 - 10.1093/ajh/hpt177
DO - 10.1093/ajh/hpt177
M3 - Article
C2 - 24072555
AN - SCOPUS:84887224544
VL - 27
SP - 720
EP - 726
JO - Journal of clinical hypertension
JF - Journal of clinical hypertension
SN - 0895-7061
IS - 5
ER -